RSSPsychiatry

Drug Development for Mental Illness: How Psychiatry Clinical Trial Sites are Meeting the Challenge of the COVID-19 Pandemic

Drug Development for Mental Illness: How Psychiatry Clinical Trial Sites are Meeting the Challenge of the COVID-19 Pandemic

| January 1, 2021

by Robert E. Litman, MD; Peter Sorantin, PhD; and Elia E. Acevedo-Diaz, MD Drs. Litman is with CBH Health, Georgetown University Medical School in Washington, DC. Dr. Sorantin is with Sorantin Outcomes, LLC, in Mountain Lakes, New Jersey. Dr. Acevedo-Diaz is with CBH Health and the National Institute of Mental Health (NIMH) in Bethesda, Maryland. […]

Continue Reading

Behavioral Activation Contributed to the Total Reduction of Depression Symptoms in the Smartphone-based Cognitive Behavioral Therapy: A Secondary Analysis of a Randomized, Controlled Trial

Behavioral Activation Contributed to the Total Reduction of Depression Symptoms in the Smartphone-based Cognitive Behavioral Therapy: A Secondary Analysis of a Randomized, Controlled Trial

| July 1, 2020

Continue Reading

The Depression Inventory Development Scale:  Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial

The Depression Inventory Development Scale: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial

| July 1, 2020

Continue Reading

Depression in Heart Failure: A Systematic Review

Depression in Heart Failure: A Systematic Review

| April 1, 2020

 

Continue Reading

Subependymal Giant-cell Astrocytoma Masquerading as Restrictive Eating Disorder and Depression in an Adolescent

Subependymal Giant-cell Astrocytoma Masquerading as Restrictive Eating Disorder and Depression in an Adolescent

| January 1, 2020

Continue Reading